Skip to main content

Table 2 The correlations between the pretreatment CRP/ALB ratio and the clinicopathological factors

From: The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer

 

Pretreatment CRP/ALB ratio

Low

High

p value

Gender

 Male

36

21

 

 Female

27

15

1.000

Age

 <65

34

19

 

 ≥65

29

17

1.000

Location of primary tumor

 Colon

36

21

 

 Rectum

27

15

1.000

Detection of unresectable tumor

 Synchronous

34

25

 

 Metachronous

29

11

0.143

Histological type

 Well, moderately

51

27

 

 Poorly, mucinous

9

3

0.744

Peritoneal dissemination

 Negative

47

33

 

 Positive

16

3

0.061

The number of organs affected by metastasis

 One organ

36

18

 

 Multiple organs

27

18

0.534

Pretreatment CEA (ng/ml)

 ≤5

9

4

 

 >5

53

31

0.765

Molecular targeted therapy

 No

17

12

 

 Yes

46

24

0.503

Pretreatment mGPS

 0

63

6

 

 1

0

21

 

 2

0

9

<0.001

Pretreatment NLR

 <3

41

13

 

 ≥3

18

22

0.003

  1. CRP/ALB ratio C-reactive protein to albumin ratio, CEA carcinoembryonic antigen, mGPS modified Glasgow prognostic score, NLR neutrophil to lymphocyte ratio